Wilkins Investment Counsel Inc. Has $18.21 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Wilkins Investment Counsel Inc. decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 125,880 shares of the company's stock after selling 2,749 shares during the period. Johnson & Johnson makes up approximately 2.6% of Wilkins Investment Counsel Inc.'s holdings, making the stock its 10th biggest position. Wilkins Investment Counsel Inc.'s holdings in Johnson & Johnson were worth $18,205,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in JNJ. IFS Advisors LLC raised its stake in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at $35,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth about $32,000. Activest Wealth Management bought a new position in Johnson & Johnson in the 3rd quarter valued at about $40,000. Finally, NewSquare Capital LLC raised its position in shares of Johnson & Johnson by 145.8% during the 4th quarter. NewSquare Capital LLC now owns 290 shares of the company's stock worth $42,000 after buying an additional 172 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Remove Ads

Analyst Ratings Changes

Several research analysts have recently issued reports on JNJ shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research report on Tuesday, January 28th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Monday, March 10th. Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Finally, Citigroup cut their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $171.33.

Johnson & Johnson Stock Up 0.2 %

Shares of Johnson & Johnson stock traded up $0.38 during midday trading on Friday, hitting $163.40. The company's stock had a trading volume of 17,012,477 shares, compared to its average volume of 7,088,732. The firm has a market capitalization of $393.76 billion, a P/E ratio of 24.57, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a 50-day simple moving average of $156.99 and a 200-day simple moving average of $156.25.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.